Get DOER Form Amendments26AUG11BC - Nccn

In the NCCN Guidelines, low-risk BCC includes nodular/superficial/nonaggressive primary BCC that is <2 cm (area L) or <1 cm (area M; location independent of size may constitute high risk) with well-defined borders, without perineural involvement, in sites without prior radiotherapy, and in patients without ...

National Comprehensive Cancer Network. Title of Guidelines (Include Version). URL. Accessed Date.

A core needle biopsy is the main method used to diagnose prostate cancer. It is usually done by a urologist. During the biopsy, the doctor usually looks at the prostate with an imaging test such as transrectal ultrasound (TRUS) or MRI, or a 'fusion' of the two (all discussed below).

New research shows that the (Prostate Screening EpiSwitch) 'PSE' blood test is 94 per cent accurate – beating the currently used prostate-specific antigen (PSA) blood test. The research team say that the new test shows significant potential as an accurate and rapid cancer screening diagnostic.

The NCCN recommends germline genetic testing, with or without pretest genetic counseling, for patients with prostate cancer and any of the following: A positive family history of cancer (eg, prostate, breast) High-risk, very-high-risk, regional or metastatic prostate cancer, regardless of family history.

The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions that currently apply to 97 percent of cancers affecting patients in the United States.

To use the NCCN Guidelines App, an individual must be a registered user on NCCN.org. There is no fee to become a registered user on NCCN.org and to view the NCCN Guidelines. Become a registered user (free) on NCCN.org. A new registration can be created from the welcome screen of the iPad and Google Play Apps as well.